Risk factors for disease progression in idiopathic pulmonary fibrosis

Thorax10.00
Volume: 75, Issue: 1, Pages: 78 - 80
Published: Oct 14, 2019
Abstract
In this retrospective study of a randomised trial of simtuzumab in idiopathic pulmonary fibrosis (IPF), prodromal decline in forced vital capacity (FVC) was significantly associated with increased risk of mortality, respiratory and all-cause hospitalisations, and categorical disease progression. Predictive modelling of progression-free survival event risk was used to assess the effect of population enrichment for patients at risk of rapid...
Paper Details
Title
Risk factors for disease progression in idiopathic pulmonary fibrosis
Published Date
Oct 14, 2019
Journal
Volume
75
Issue
1
Pages
78 - 80
Citation AnalysisPro
  • Scinapse’s Top 10 Citation Journals & Affiliations graph reveals the quality and authenticity of citations received by a paper.
  • Discover whether citations have been inflated due to self-citations, or if citations include institutional bias.